PDCD1 and non-small cell lung carcinoma: Several elegant phase III randomized clinical trials have shown that first‐line PD‐1 blockade plus chemotherapy could dramatically improve the progression‐free survival (PFS) and/or overall survival (OS) in patients with advanced NSCLC.4, 5, 6, 7, 8, 9, 10, 11